Clinical trials: HIV-infection/AIDS
HIV Infections
The Effectiveness of Ritonavir Plus Zidovudine Plus Lamivudine in HIV-Infected Patients
To determine whether administration of a highly active antiretroviral treatment regimen consisting of ritonavir (ABT-538), zidovudine (AZT), and lamivudine (3TC) is associated with the restoration of delayed type hypersensitivity…
- Trial name
- NCT00001075
- Testing
- Ritonavir, Lamivudine, Zidovudine
- Where
- 3 sites in United States
- Volunteers
- 55 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Infection, Human Immunodeficiency Virus, HIV Infections
An Efficacy, Safety, and Tolerability Study Comparing Dolutegravir Plus Lamivudine With Dolutegravir Plus Tenofovir/Emtricitabine in Treatment naïve HIV Infected Subjects (Gemini 1)
This study will compare safety, efficacy, and tolerability of a two drug regimen of dolutegravir (DTG) plus (+) lamivudine (3TC) administered once daily with DTG plus two nucleoside reverse transcriptase inhibitors (Tenofovir…
- Trial name
- NCT02831673
- Testing
- Dolutegravir (DTG), Lamivudine (3TC), Tenofovir disoproxil fumarate/Emtricitabine (TDF/FTC FDC)
- Where
- 90 sites in United States, Argentina and 16 more
- Volunteers
- 719 people
- Sponsor
- ViiV Healthcare
HIV Infections
Long-Term Supervised Treatment Interruption in HIV-Infected Patients
This trial is aimed at studying the safety of long term supervised treatment interruption in HIV infected patients with CD4 over 350/mm3 and plasma HIV RNA under 50 000/mL.
- Trial name
- NCT00118677
- Testing
- Treatment interruption
- Where
- France
- Volunteers
- 130 people
- Sponsor
- French National Agency for Research on AIDS and Viral Hepatitis
HIV Infections
Open-Label Program of Dideoxycytidine ( ddC ) to Be Used in Combination With Zidovudine ( AZT ) for Treatment of Advanced HIV Disease
To provide zalcitabine ( dideoxycytidine; ddC ) for use with zidovudine ( AZT ) in patients with advanced HIV infection. To observe serious toxicities in this population.
- Trial name
- NCT00002081
- Testing
- Zidovudine, Zalcitabine
- Where
- United States
- Sponsor
- Hoffmann-La Roche
HIV Infections
Non-virologic Methods to Diagnose Treatment Eligibility in HIV-exposed Infants
This study is designed to develop and evaluate a set of non-virologic diagnostic algorithms to monitor HIV-exposed children of unknown infection status for treatment eligibility during the first year of life.
- Trial name
- IDX (NCT01222130)
- Where
- 3 sites in Zambia
- Volunteers
- 1,126 people
- Sponsor
- University of North Carolina, Chapel Hill
Hepatitis C, HIV
Swiss HCVree Trial
The investigators aim at investigating the efficacy of grazoprevir/elbasvir ±ribavirin in HIV-positive MSM participating in the SHCS in a broader setting of coinfected MSM.
- Trial name
- HCVree (NCT02785666)
- Testing
- grazoprevir/elbasvir, ribavirin, Behavioural Intervention
- Where
- Switzerland
- Volunteers
- 150 people
- Sponsor
- University of Zurich
HIV Infections
Effectiveness of Treating HIV-Positive Patients With an HIV Vaccine (Remune)
The purpose of this study is to see if it is effective to add an HIV vaccine (Remune) to the anti-HIV drug combination of Combivir (zidovudine plus lamivudine) and nelfinavir.
- Trial name
- NCT00005002
- Testing
- Lamivudine/Zidovudine, HIV-1 Immunogen, Nelfinavir mesylate
- Where
- United States
- Volunteers
- 688 people
- Sponsor
- Agouron Pharmaceuticals
Human Immunodeficiency Virus I Infection, Human Immunodeficiency Virus II Infection
A Study to Evaluate the Performance, Usability, and Result Interpretation of INSTI® HIV Self-Test
The objective of this study is to evaluate the performance, usability, and result interpretation of the INSTI® HIV Self-Test (referred to INSTI® HIV ST) in the intended use population across the United States (US).
- Trial name
- NCT06368453
- Testing
- INSTI® HIV Self-Test
- Where
- United States
- Volunteers
- 1,728 people, healthy volunteers welcome
- Sponsor
- bioLytical Laboratories
Chronic Infection With HIV
RAL+ATV/r in Comparison With TDF/FTC (or 3TC) +ATV/r in HIV Infected Patients
The purpose of this pilot study is to assess the efficacy and safety of the combination of RAL+ATV/r in comparison with TDF/FTC+ATV/r in HIV-1 infected patients presenting virologic failure and PI and TDF naïve.
- Trial name
- ARTE (NCT01829802)
- Testing
- Ritonavir boosted Atazanavir, Raltegravir, TDF/FTC (or 3TC)
- Where
- 2 sites in Argentina
- Volunteers
- 50 people
- Sponsor
- Pedro Cahn
HIV Infections
Evolution of HIV Reservoir, Inflammation and Microbiota Footprint of PLWH Switching to Long-acting Injectable Treatment Compared to Patients on Oral Dual or Triple Anti-integrase-based Therapy
In the last 40 years of HIV history, we have managed to attain most of our therapeutic objectives, namely virological suppression of most patients and sufficient immune reconstitution.
- Trial name
- LAMIVIH (NCT05303337)
- Testing
- Stool sampling, Blood plasma collection
- Where
- France
- Volunteers
- 120 people
- Sponsor
- Hôpital Européen Marseille
HIV Infections
A Multicenter, Double Blind, Comparative Study of Zidovudine Alone Versus Zidovudine and Acyclovir as Treatment for HIV-Infected Patients With CD4+ Counts Less Than 200 Cells/mm3
Original design: The study's purpose is to compare the effects of zidovudine (AZT) alone to the combination of AZT and acyclovir (ACV) to determine if AZT/ACV is associated with a lower death rate and fewer AIDS related…
- Trial name
- NCT00000712
- Testing
- Zidovudine, Acyclovir
- Where
- 8 sites in United States
- Volunteers
- 400 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Lymphoma
Carmustine, Etoposide, Cyclophosphamide, and Stem Cell Transplant in Treating Patients With HIV-Associated Lymphoma
RATIONALE: Giving high-dose chemotherapy drugs, such as carmustine, etoposide, and cyclophosphamide, before a peripheral blood stem cell transplant stops the growth of cancer cells by stopping them from dividing or killing them.
- Trial name
- NCT00641381
- Testing
- carmustine, cyclophosphamide, etoposide
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- City of Hope Medical Center
HIV Infections
Once a Day (QD) - Twice a Day (BID) Clinical Trial: Didanosine, Lamivudine and Efavirenz Versus Zidovudine, Lamivudine and Efavirenz in the Starting Treatment of HIV
The purpose of this study is to compare the antiviral activity of two treatment groups for HIV chronic infection: a QD regimen of didanosine, lamivudine and efavirenz versus a BID regimen of zidovudine, lamivudine and efavirenz.
- Trial name
- NCT00256828
- Testing
- didanosine + lamivudine + efavirenz
- Where
- 57 sites in Spain
- Volunteers
- 360 people
- Sponsor
- Clinical Trial Agency of HIV Study Group
AIDS Dementia Complex, HIV-1-Associated Cognitive Motor Complex
Effect of Cenicriviroc on HIV Neurocognitive Impairment
The study hypothesis is that cenicriviroc will improve cognition in HIV infected individuals with cognitive impairment. The investigators will study the effect of cenicriviroc on cognition in 24 subjects over a 24 week period.
- Conditions
- AIDS Dementia Complex, HIV-1-Associated Cognitive Motor Complex, Human Immunodeficiency Virus
- Trial name
- NCT02128828
- Testing
- cenicriviroc
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- University of Hawaii
HIV-1 Infection
Study to Evaluate the Safety and Efficacy of Bictegravir/Emtricitabine/Tenofovir Alafenamide Versus Abacavir/Dolutegravir/Lamivudine in Human Immunodeficiency Virus-1 (HIV-1) Infected, Antiretroviral Treatment-Naive Adults
The primary objective of this study is to evaluate the efficacy of a fixed dose combination (FDC) containing bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) versus a FDC containing abacavir/dolutegravir/lamivudine…
- Trial name
- NCT02607930
- Testing
- ABC/DTG/3TC, B/F/TAF
- Where
- 121 sites in United States, Belgium and 8 more
- Volunteers
- 631 people
- Sponsor
- Gilead Sciences
HIV Infection
Using Multimedia Technologies to Disseminate an HIV Prevention
This RCT will randomly assign 40 of the CBOs to receive the Multimedia intervention and training package (Multimedia)and the other 40 to receive the original, manualized Connect intervention and training package (Traditional).
- Trial name
- NCT01863537
- Testing
- Multimedia Connect, Traditional Connect
- Where
- United States
- Volunteers
- 253 people, healthy volunteers welcome
- Sponsor
- Columbia University
HIV/AIDS
Community-based, Peer-delivered PrEP for Female Sex Workers in Rural Uganda: The Peers for PrEP (P4P) Study
The overall goal of the P4P: Peers for PrEP (pre-exposure prophylaxis) study is to pilot test a peer-led and delivered intervention for biomedical HIV prevention that is tailored to women who engage in sex work in southwestern…
- Trial name
- P4P (NCT06353295)
- Testing
- P4P intervention
- Where
- Uganda
- Volunteers
- 140 people, healthy volunteers welcome
- Sponsor
- University of California, San Francisco
HIV Infection
Cellulose Sulfate and HIV Transmission Among Women
The purpose of the study is to determine the effect of cellulose sulfate on the transmission of HIV to women via vaginal intercourse.
- Trial name
- NCT00153777
- Testing
- Cellulose Sulfate gel (6%)
- Where
- 5 sites in Benin, India and 2 more
- Volunteers
- 1,428 people, healthy volunteers welcome
- Sponsor
- CONRAD
HIV Testing, HIV Infections
OraQuick® HIV Self-Test Study in Canada
Oral fluid based HIV Self-testing (HIVST) provides another innovative and simple option to increase opportunities for HIV testing.
- Trial name
- OQHIVST (NCT05020353)
- Testing
- OraQuick® HIV Self-Test
- Where
- 7 sites in Canada
- Volunteers
- 951 people, healthy volunteers welcome
- Sponsor
- Unity Health Toronto
HIV Infections
Evaluating the Pharmacokinetics, Safety, and Tolerability of Doravirine (MK-1439) and Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (MK-1439A) in HIV-1-Infected Children and Adolescents
The purpose of this study was to evaluate the pharmacokinetics, safety, and tolerability of doravirine (also called MK-1439 or DOR) and doravirine/lamivudine/tenofovir disoproxil fumarate (also called MK-1439A or DOR/3TC/TDF) in…
- Trial name
- NCT03332095
- Testing
- Doravirine (DOR), Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (DOR/3TC/TDF), Antiretroviral (ARV) medications
- Where
- 8 sites in United States, South Africa and 1 more
- Volunteers
- 55 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.